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ABSTRACT
MutLa, a heterodimer of MLH1 and PMS2, plays a
central role in human DNA mismatch repair. It
interacts ATP-dependently with the mismatch detec-
tor MutSa and assembles and controls further repair
enzymes. We tested if the interaction of MutLa with
DNA-bound MutSa is impaired by cancer-associated
mutations in MLH1, and identified one mutation
(Ala128Pro) which abolished interaction as well as
mismatch repair activity. Further examinations
revealed three more residues whose mutation inter-
fered with interaction. Homology modelling of MLH1
showed that all residues clustered in a small acces-
sible surface patch, suggesting that the major
interaction interface of MutLa for MutSa is located
on the edge of an extensive b-sheet that backs the
MLH1 ATP binding pocket. Bioinformatic analysis
confirmed that this patch corresponds to a con-
served potential protein–protein interaction inter-
face which is present in both human MLH1 and its
E.coli homologue MutL. MutL could be site-
specifically crosslinked to MutS from this patch,
confirming that the bacterial MutL–MutS complex is
established by the corresponding interface in MutL.
This is the first study that identifies the conserved
major MutLa–MutSa interaction interface in MLH1
and demonstrates that mutations in this interface
can affect interaction and mismatch repair, and
thereby can also contribute to cancer development.
INTRODUCTION
The activity of the mismatch repair system elevates replication
ﬁdelity by several hundredfold through the removal of a wide
variety of polymerase errors, including insertion–deletion loops
that can form during the replication of repetitive sequences
(1–3). The system has been conserved throughout evolution.
In humans, germline mutations in mismatch repair genes,
predominantly MLH1 and MSH2, underlie the Lynch
syndrome (also called hereditary non-polyposis colorectal
cancer, HNPCC), a hereditary cancer predisposition which
accounts for 3-5% of all colorectal cancer cases (3–5).
Mismatch repair in humans is initiated by one of two MutS
heterodimers, either MutSa (MSH2–MSH6) or MutSb
(MSH2–MSH3), depending on the type of mismatch to be
repaired (6-8). After mismatch binding by this heterodimer,
a MutL heterodimer is recruited. This is predominantly
MutLa (MLH1–PMS2), although a contribution of MutLg
(MLH1–MLH3) has also recently been reported for a subset
of replication errors (9-11). The human MutSa/b and MutLa/
g heterodimers have evolved from the homodimeric bacterial
predecessors MutS and MutL. The heterodimeric subunits of
the human proteins share a common architecture, but diverge
in structural and functional details.
Together with a MutS protein, the MutL protein directs
the exonucleolytic degradation of a stretch of the error-
containing strand including the mismatched base (12–17).
Repair is completed by DNA re-synthesis on the emerging
gap. The overall mechanism of mismatch repair appears to
be similar in all organisms except for identiﬁcation of the
faulty DNA strand (that has to be repaired), which is
performed in E.coli and some other bacteria by MutH, an
endonuclease that binds in a site-directed manner to the tran-
siently hemimethylated DNA that arises during bacterial
replication (18,19). Since eukaryotes lack this transient
hemimethylation, other ways of strand discrimination are
possible [reviewed in (1,2)].
While the role of MutS proteins as mismatch-detectors
is well established, the contribution of MutL proteins to
repair has remained more elusive. Recently, Modrich and
co-workers have demonstrated an endonucleoylic activity of
human MutLa residing in the C-terminal domain of PMS2
(20). Functionally, MutL proteins have been shown to confer
termination of the exonucleolytic degradation of the faulty
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of their most striking features is that they interact with a wide
variety of other proteins, including the endonuclease MutH,
the DNA clamp b and DNA helicase II (UvrD) in bacterial
systems, and the DNA clamp PCNA, topoisomerase II, and
exonuclease I as well as several factors involved in DNA
damage response in higher organisms [for review, see
(1,2)]. They are therefore thought to act as matchmakers
that assemble other enzymes to the mismatched site to
accomplish repair and initiate DNA damage signalling. The
most important protein interaction partners for MutL proteins,
however, are the MutS proteins, since these two factors
represent the core of the repair machinery.
The N-terminal domains (NTD) of MutL proteins contain
an ATPase of the GHKL class (22,23), while the C-terminus
confers dimerization (24,25) and contains in the PMS2
protein the metal binding site essential for endonucleolytic
function (20). The C-terminal dimerization is constitutive,
but a second dimerization interface in the NTD of E.coli
MutL has been shown to confer an ATP-dependent, reversible
dimerization (26). This transient dimerization is required for
ATP hydrolysis and represents a common theme among
GHKL-ATPases (22). The resulting ATPase cycle, which
includes ATP binding, transient N-terminal dimerization,
hydrolysis, subsequent separation of the N-termini and
release of ADP, has been suggested to be a switch in the
repair process (26), although its function is unknown. MutL
has been found to bind DNA, and an association of DNA
binding to the activity of the ATPase has been documented
(27,28). The ATPase, whose functionality is vital for repair
activity in bacterial and human MutL (29,30), likely controls
binding (and activation) of the downstream repair factors
MutL interacts with in dependence of the progression of
repair.
The protein complex of MutS and MutL initiates and
controls the mismatch repair reaction. Its detailed character-
ization is therefore essential for understanding mismatch
repair. The conditions required for formation of complexes
of MutL and MutS proteins have been investigated exten-
sively (28,29,31,32). Their characterization is complicated
by the transient and dynamic nature of the complex. We
have previously shown that the N-terminus (residues 1–505)
of the MutLa subunit MLH1 is required and sufﬁcient for
interaction of human MutLa and MutSa (31). Based on the
hypothesis that loss of MutLa–MutSa interaction may inter-
fere with DNA mismatch repair, we screened a set of cancer-
associated missense mutations in MLH1 for their effect on
interaction. We here describe the identiﬁcation of a surface
cluster of residues whose mutation disrupts MutLa–MutSa
interaction and affects mismatch repair activity, suggesting
a mechanism by which hereditary mutations in this region
can produce a cancer predisposition.
MATERIALS AND METHODS
Strains, cell lines, plasmids, enzymes and reagents
Poly [d(I*C)] was purchased from Boehringer Mannheim
(Mannheim, Germany), ATP, RNAse A and Proteinase K
were from Sigma-Aldrich (St Louis, MO, USA). Restriction
enzymes N.BstNBI, N.AlwI and AseI as well as T4 DNA
ligase were from New England Biolabs (Ipswich, MA,
USA). Anti-hMLH1 (G168–728) was from Pharmingen
(San Diego, CA, USA), anti-hPMS2 (B-3) was from
Santa Cruz Biotechnology (Santa Cruz, CA, USA). Anti-
hMSH2 (M34520) and anti-hMSH6 (G70220) were pur-
chased from Transduction Laboratories (Lexington, KY,
USA). HEK293T cells were grown in DMEM nut mix F-12
(HAM) with 10% FCS. HCT-116 cells were kindly provided
by Dr C. Richard Boland (University of California, CA,
USA) and grown in DMEM with 10% FCS. Oligonucleotides
were purchased from BioSpring (Frankfurt, Germany) and
from Qiagen (Valencia, CA, USA). Streptavidin-coupled
M-280 beads were from Dynal (Oslo, Norway).
E.coli K12 strains CC106 (P90C [araD[lac-pro)XIII
(F’laciZ proB
+] (33), TX2652 (CC106 mutL::W4 (BsaAI;
Kan
r) and TX2928 (CC106 mutH471::tn5;Kan
r) (34) and
the pET-15b (Novagen) derived plasmids pTX412 and
pTX418 containing the mutS and mutL genes, respectively,
under control of the T7 promotor were kindly provided by
Dr M. Winkler (34). Plasmid pMQ402 (His6-MutH), a
pBAD18 derivative, was a kind gift from Dr M. Marinus
(35). For protein expression of MutS and MutL, the E.coli
strain HMS174(lDE3) (Novagen, Darmstadt, Germany)
was used. For MutH, the E.coli strain XL1 blue (Stratagene,
La Jolla, CA) was used. Pfu DNA polymerase was expressed
and puriﬁed as described (36).
The pcDNA3 expression vector (Invitrogen, Carlsbad, CA,
USA) containing the entire open reading frame of human
MLH1 was a gift of Dr Hong Zhang (Huntsman Cancer Insti-
tute, University of Utah, Salt Lake City, UT, USA). The
pSG5 expression vector (Stratagene, La Jolla, CA, USA)
containing full-length human PMS2 cDNA was provided by
Dr Bert Vogelstein (Johns Hopkins Oncology Center, Balti-
more, MD, USA). Amino-acid positions in MLH1 refer to
the 756 aminoacid MLH1 sequence (NCBI accession no.
AAC50285). All mutant MLH1 constructs used in this
study were generated using the QuickChange Site Directed
Mutagenesis Kit (Stratagene, La Jolla, CA, USA) according
to the manufacturer’s instructions with suitable oligonu-
cleotides. The deletion mutant of MLH1 which lacks the
N-terminal helix A’ (aa 2-25) was also generated by site-
directed mutagenesis using deletion-primers that spanned
the neighbouring sequence (50-ggaattcgagctcatatgcagcggccag
ctaatgc-30 and its reverse complement). Before use, all mutant
constructs were controlled by direct sequencing (BigDye v1.1
chemistry and ABI 3100 sequencer, Applied Biosystems,
Weiterstadt, Germany).
Transfection and extract preparation
HEK293T cells were transfected using calcium phosphate
precipitation according to standard procedures (37). Cells
were harvested after 24 h and whole cell extracts were
prepared. Cells were washed with PBS and re-suspended in
2 times the packed cell volume of hypotonic buffer (10 mM
HEPES (pH 7.9), 5 mM MgCl2, 10 mM NaCl, 10 mM NaF,
0.1 mM EDTA, 0.2 mM PMSF, 0.5 mM DTT). The
suspension was frozen at  80 C and thawed on ice for
lysis. This suspension containing both nuclei and cytoplas-
matic extract was supplemented with an identical volume
of hypertonic buffer [10 mM HEPES (pH 7.9), 5 mM
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PMSF, 0.5 mM DTT, 34% glycerol]. The suspension was
rocked on ice for 30 min and then centrifuged (4 C, 21 000
g). The supernatant (whole cell extract) was stored in aliquots
at  80 C. Expression of the desired protein was veriﬁed by
SDS–PAGE and immunoblotting in comparison to extracts
of untransfected HEK293T cells (negative control) and
extracts of 293 or TK6 cells (expressing wild-type levels of
MMR-proteins) as positive control. Nuclear extracts for the
interaction assay were prepared from HCT-116 cells as
described previously (28).
Nuclear extracts for mismatch repair assays were prepared
using a similar procedure. In short, cells were re-suspended in
three times their packed cell volume in ice-cold hypotonic
buffer (20 mM HEPES pH 7.5, 5 mM KCl, 0.5 mM
MgCl2, 0.5 mM DTT, 0.2 mM PMSF) and lysed with Dounce
pestle B until lysis was sufﬁcient. After centrifugation
(2000 g 4 C 5 min), the cytoplasmatic supernatant was
removed and again centrifuged (16 000 g 4 C 5 min) for
removal of residual supernatant. The pellet was re-suspended
in re-suspension-buffer (20 mM HEPES-KOH pH 7.5, 10%
sucrose, 1 mM DTT, 0.2 mM PMSF) with Complete  pro-
tease inhibitors and high-salt buffer (50 mM HEPES-KOH
pH 7.5, 10% sucrose, 840 mM KCl) was added under agita-
tion. Extraction was performed for 30 min and extracted
nuclei were removed by centrifugation (21 000 g, 4 C,
30 min). The supernatant was dialysed 6 h against 100
times the volume of buffer (25 mM HEPES pH 7.6,
100 mM KCl, 0.1 mM EDTA, 0.5 mM DTT, 0.2 mM
PMSF). The extract was centrifuged (21 000 g, 4 C, 10
min), snap-frozen in liquid nitrogen and stored in aliquots
at –80 C.
MutSa–MutLa-interaction
The MutSa–MutLa-interaction was assessed essentially as
described previously (31). All steps were performed on ice.
Cell extract (150 mg protein, consisting of 145 mg HCT-116
extract and 5 mg extract of HEK293T cells containing the mu-
tated MutLa protein) was incubated in 20 mM Tris–HCl, pH
7.9, 50 mM NaCl, 1.5 mM MgCl2, 5% glycerol, 1 mM
EDTA, 0.2 mM PMSF, 0.5 mM DTT and 1 mgp o l y
[d(I*C)] in a total volume of 300 ml for 5 min on ice. For
each experiment, two identical samples from one master
mix were prepared. Both samples were added to an aliquot
of streptavidine beads coupled with 200 bp homoduplex
DNA substrate as detailed in (31). After 20 min incubation,
ATP was added to one sample to a ﬁnal concentration of
250 mM. After 5 min, the beads were collected with a magnet
and the supernatant was taken off, the cup centrifuged and
residual supernatant removed. The beads were re-suspended
in 20 ml elution buffer (700 mM NaCl, 20 mM Tris–HCl,
pH 7.9, 1.5 mM MgCl2, 5% glycerol, 1 mM EDTA,
0.2 mM PMSF and 0.5 mM DTT) and incubated for 5 min.
The beads were collected and the supernatant stored for anal-
ysis. A second elution step was performed with 20 ml elution
buffer as above, only with 1000 mM NaCl. This elution was
also analysed by SDS–PAGE and immunoblotting and veri-
ﬁed that ATP has taken effect, since it abolishes hMutSa
signals in this elution fraction. Although this elution has
always been performed as a control, the data has been omitted
in the ﬁgures. Furthermore, identical concentration of the
MutLa heterodimer has always been checked by an
immunoblot of the incubation mixture.
Mismatch plasmid construction
The pUC19CPDC plasmid used for construction of the
mismatched substrate were kindly provided by Dr John B.




 ) from Stratagene. The plasmid substrate for the mis-
match repair assay was synthesized following the published
procedure (38–41) with some minor modiﬁcations. In short,
pUC19CPDC (50 mg) was nicked at two sites with 32 bp
distance with N.BstNBI (usually 30 U) for 3 h. Quantitative
nicking was assured by running aliquots of the reaction on an
agarose gel, and digestion was continued afterwards with
additional enzyme for one more hour. The digested single-
stranded oligomer was released and captured by denaturing
at 85 C for 5 min in the presence of 50-fold excess antisense-
oligomer WHCPDPuriAS (50-GCGGATATTAATGTGACG-
GTAGCGAGTCGCTC-30) and subsequent slow cooling to
room temperature. Oligomers were removed by centrifuga-
tion through Microcon-100 columns and extensive washing
with TE buffer. Gapped plasmid was ligated with a 10-fold
molar excess of WHpCPD7 (50-pGCGGATATTAATGTGA-
CGGTAGCGAGTCGCTC-30). Ligation was carried out
overnight with T4 DNA ligase (50 U) at 16 C. Ligated prod-
uct was ethanol precipitated and subsequently treated with
N.AlwI (50–100 U) until quantitatively nicked as judged by
electrophoresis of small aliquots. Enzyme was heat inacti-
vated (80 C 20 min) and the nicked mismatch plasmid was
puriﬁed by centrifugation through Microcon-100 columns.
The resulting plasmid (named pUC19CPDC-GTN) contains
one AseI restriction site, a GT mismatch within an overlap-
ping AseI/EcoRV restriction site as well as a nick in the
DNA 141 bp from the mismatched site, which serves to direct
mismatch repair to convert the GT mismatch to AT, thereby
restoring the AseI restriction site. Digestion of this prepara-
tion with AseI yielded only linearized vector, but no detec-
table fragments. Digestion with AseI and EcoRV showed
that  10% of the preparation was cleavable with EcoRV,
conﬁrming that the majority of the original pUC19CPDC
was transformed to mismatched substrate. Since repair of
pUC19CPDC-GTN is assessed by restoration of the second
AseI restriction site, the residual EcoRV-cleavable plasmid
did not interfere with the mismatch repair assay. The pres-
ence of the mismatch and the nick were additionally veriﬁed
by direct sequencing of pUC19CPDC-GTN.
MMR assay
Mismatch repair reactions were essentially performed as
described elsewhere (40,42). In short, the reaction was per-
formed in 15 ml total volume with reaction buffer (20 mM
Tris–HCl pH 7.6, 110 mM KCl, 5 mM MgCl2,1m M
glutathione, 50 mg/ml BSA, 1.5 mM ATP, 0.1 mM each
dNTP), 100 ng DNA substrate and 50 mg nuclear extract of
HEK293T cells, which are deﬁcient in mismatch repair
(43). Where indicated, reactions were supplemented with
5 mg extract from HEK293T cells expressing recombinant
hMutL constructs. Reactions were incubated at 37 C for 20
min and terminated with 50 ml stop-buffer (24 mM EDTA
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incubation for 15 min at 37 C. Plasmids were extracted from
the reaction mixture by phenol extraction and puriﬁed by
ethanol co-precipitation with tRNA. Subsequent digestion
with AseI and RNAse A produced two smaller fragments
besides the linearized vector when repair was successful.
Restriction digests were separated on 2% agarose gels,
stained with ethidium bromide and documented by UV-
transillumination and Polaroid photography. Levels of mis-
match repair were quantiﬁed using Quantity One Software
v4.6.1 (Bio-Rad, Hercules, CA, USA) by dividing the volume
of the two repair bands by the total volume of all three bands.
Relative repair efﬁciency was calculated by dividing the
value of the mutant through the value of a wild-type protein
preparation that had been expressed, processed and tested in
parallel.
DNA substrates for photocrosslinking
Linear heteroduplex substrates were generated by annealing
two 484 bp PCR products ampliﬁed by Taq-DNA polymerase
with a single GATC site at position 210 and a G/C or an A/T
bp at position 385 using plasmids and primers as described
previously (44). This procedure results in a mixture of 50%
homoduplex substrates (G/C and A/T) and 50% heteroduplex
substrates (G/T and A/C). In general 40–60% of this DNA
was cleavable by MutH in a mismatch and MutS dependent
manner.
Purification of MutLa constructs
Details of the puriﬁcation of MutLa and its characterization
are to be published in a separate manuscript. In short, the
cDNA of PMS2 was cloned from pSG5 into pEBG-2T
via the BamHI restriction site. This placed PMS2 downstream
of the coding sequence for Glutathion-S-Transferase (GST).
HEK293T cells were co-transfected with MLH1 (wildtype
or mutant) and pEBG-2T PMS2. Cells were lysed after two
days in lysis buffer (50 mM Tris–HCl pH 7.4, 0.27 M
sucrose, 1 mM EDTA, 1 mM EGTA, 1% Triton X-100,
0.1% b-mercaptoethanol, 0.2 mM PMSF), centrifuged and
the supernatant incubated with 0.3 ml glutathion Sepharose
for 1 h at 4 C. The suspension was applied to a column,
allowed to settle and drained by gravity ﬂow. The Sepharose
was washed with 5 ml of lysis buffer and 10 ml of washing
buffer (50 mM Tris–HCl pH 7.5, 1 mM EGTA, 0.1%
b-mercaptoethanol). Bound protein was eluted with washing
buffer supplemented with 40 mM reduced glutathion and 0.27
M sucrose. This procedure yielded 50–70% pure MutLa.
ATPase assays
ATPase activity of partially puriﬁed GST–MutLa was
assessed essentially as published before (29). In short,
GST–MutLa (500 ng) was incubated in a 15 ml reaction vol-
ume containing 20 mM Tris–HCl pH 7.5, 120 mM NaCl,
5 mM MgCl2, 100 mg/ml BSA, 1 mM DTT, 400 mM ATP,
and 0.2 mCi adenosine 50-[g-
32P]triphosphate. After incuba-
tion at 37 C for 30 min, reactions were terminated by
addition of 1.5 ml 10 M formic acid. Aliquots of 5 ml were
loaded onto Polygram CEL300 PEI TLC plates, developed
in 0.5 M lithium chloride/1 M formic acid and quantiﬁed
using a Typhoon Imager and ImageQuant 5.1 software.
ATPase activity was calculated as mM of released phosphate
per pmol pure GST–MutLa per h, and values from parallel
mock experiments (without protein) were substracted to
eliminate background.
Purification of bacterial mismatch repair proteins




N131C, (46)] and MutS
proteins were puriﬁed by Ni-NTA chromatography essen-
tially as described (34,45). When necessary, proteins were
puriﬁed by gel ﬁltration on a Superdex200 column (Pharma-
cia). MutH proteins were stored at  20 C in 10 mM HEPES-
KOH, 500 mM KCl, 1 mM EDTA, 1 mM DTT, 50%
glycerol, pH 7.9. MutL and MutS proteins were snap-frozen
in liquid nitrogen and stored at  70 C in 10 mM HEPES-
KOH, 200 mM KCl, 1 mM EDTA, pH 7.9. Protein concen-
trations were determined using theoretical extinction
coefﬁcients (47).
Crosslinking studies
Crosslinking was performed either with the thiol-speciﬁc
homobifunctional reagent BM[PEO]4 or the heterobifunc-
tional reagent 4-maleimidobenzophenone (MBP), which
contains one thiol-speciﬁc activity and can furthermore be
photocrosslinked non-speciﬁcally to nearby residues. The
concentration of crosslinker was titrated to achieve optimal
conditions for speciﬁc crosslinking. For crosslinking with
BM[PEO]4, MutS (400 nM), SC-MutL
N131C (1000 nM) and
heteroduplex DNA (484 bp, mixture of G/T and A/C mis-
match; 100 nM) were incubated in the presence of the indi-
cated nucleotide (1 mM) in 10 mM HEPES-KOH, pH 7.5,
5 mM MgCl2, 125 mM KCl. BM[PEO]4 was added to a
ﬁnal concentration of 50 mM and the reaction was allowed
to proceed for 1 min at 37 C. Crosslinking was quenched
by the addition of 50 mM DTT and samples were separated
by SDS–PAGE (10% gel) followed by Coomassie staining
PageBlue from Fermentas (Hanover, MD, USA).
For photocrosslinking, MutL
N131C (10 mM) was incubated
with or without MutH
C96S (2.5 mM) with 500 mM
4-maleimidobenzophenone (MBP, Sigma) in 10 mM Tris,
5 mM MgCl2, pH 7.9 in the presence of 4 mM nucleotide,
ATP or AMP-PNP, for 30 min at room temperature. Reaction
was stopped by adding a 5-fold molar excess of DTT over
thiol-speciﬁc reagent. For photocrosslinking 2 mM modiﬁed
MutL, 500 nM MutH, 1 mM MutS
wt, 0.8 mM nucleotide,
25 nM 484 bp mismatch DNA, in 10 mM Tris, pH 7.9,
5 mM MgCl2, 125 mM KCl were irradiated for 25 min at
354 nm with a handheld UV lamp at a distance of 5 cm.
The samples were separated by SDS–PAGE and detected
by Coomassie staining.
Tryptic digests and mass spectrometry for identiﬁcation of
crosslinked products were performed as described before
(46).
Structural analysis
Protein sequence were retrieved from the NCBI databases
(48) using BLAST (49). An alignment of sequences homo-
logous to human MLH1 was computed by ClustalW (50)
and improved by minor manual modiﬁcations in SeaView
(51). A homology-derived 3D structure model of human
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(52) with a sequence–structure alignment extracted from the
multiple sequence alignment of MHL1 homologues and
based on the PDB structure 1b62 (chain A) of E.coli MutL
complexed with ADP-Mg
2+ as template (26,53) [E-value
10
 53 and sequence identity 35%; see Supplementary Figure
A for the sequence–structure alignment, which was prepared
in GeneDoc (54)]. The secondary structure assignment of
1b62 was taken from the DSSP database (55).
The ProMate server (56) was used for calculation of the
probability of the residues to contribute to a transient
heterodimeric protein interaction of either the MLH1 homo-
logy model or the structure of E.coli MutL (PDB 1b63).
The analysis was performed with standard conﬁguration
except that ‘Evolutionary conserved position’ and ‘Water
molecules’ were disabled.
For surface-mapping of phylogenetic conservation
information, we performed a BLASTP search with the sequ-
ences of MLH11–335 and E.coli MutL1–329. The 250 best hits
were extracted and aligned with ClustalW. We manually
extracted 84 sequences from the MLH1 alignment and
79 sequences from the MutL alignment showing highest
similarities within the region of b-strands 3–5 to exclude
more distant members of these protein families. The extracted
sequences were analyzed by ConSurf 3.0 (57).
We used the PyMOL Molecular Graphics System
(2002) (DeLano Scientiﬁc, San Carlos, CA, USA, http://
www.pymol.org) to create protein structure images and
applied the Color_B script to project the results of the
ConSurf and ProMate analyses onto the protein surfaces.
The BioEdit sequence alignment editor v7.0.1 (www.mbio.
ncsu.edu/BioEdit/bioedit.html) was used for drawing of
alignments.
Protein separation and detection
The proteins were separated on 10% polyacrylamide gels,
followed by blotting on nitrocellulosemembranes and anti-
bodydetection using standard procedures.
Accession numbers
The NCBI accession numbers of the sequences in Figure 2B
are: CAA77850 (E.coli), MLH1: AAH06850 (human),
NP_081086 (mouse), NP_112315 (rat), AAC19117 (fruitﬂy),
XP_320342 (anopheles), XP_329015 (neurospora crassa),
NP_499796 (worm), P38920 (baker’s yeast), AAK25988
(thale cress), NP_596199 (ﬁssion yeast); PMS: P54278
(hPMS2), XP_213712 (rat), NP_032912 (mouse), AAL39978
(fruitﬂy), XP_308635 (anopheles), XP_328726 (neurospora
crassa), NP_505933 (worm), AAM00563 (baker’s yeast),
BAC42424 (thale cress), CAB10113 (ﬁssion yeast).
RESULTS
The cancer mutation MLH1 Ala128Pro abolishes
MutLa–MutSa interaction and mismatch repair
For a closer characterization of the interaction of human
MutLa (MLH1–PMS2) with MutSa, we tested whether this
interaction is affected by mutations observed in the hereditary
Lynch cancer syndrome, which is most frequently caused by
germline mutations in MLH1 (58,59). We have previously
shown that the interaction of MutLa with MutSa is predomi-
nantly conferred by MLH1, since the MLH1 subunit, but not
the PMS2 subunit, interacts efﬁciently (31). This study also
showed that an MLH1 fragment containing the N-terminal
domains (NTD; MLH11–505) was required and sufﬁcient for
interaction. We therefore selected a set of Lynch syndrome
mutations identiﬁed in the NTD of MLH1: Asn64Ser,
Cys77Tyr, Thr117Met, Ala128Pro and Arg265Cys
(Figure 1A). In addition, we included Asp132His, a mutation
which has recently been associated with low-penetrance her-
editary colorectal cancer (60). Vectors containing the mutant
MLH1 cDNAs were generated and transfected into HEK293T
cells either alone or co-transfected with PMS2. The MLH1
gene is transcriptionally silenced in HEK293T cells, which
causes a concomitant loss of PMS2, whose stability depends
on MLH1 [(31,43,61); Figure 1B, WB, lane 1]. This allows
expressing and analysing MutLa variants in this cell line
without interference of endogenous MutLa. Immunoblotting
of cell extracts conﬁrmed that mutant and wild-type MLH1
proteins were expressed equally well (Figure 1B, WB, lanes
2–7) except for the MLH1
C77T variant, which showed attenu-
ated expression suggestive of impaired protein stability
(data not shown) and was therefore excluded from further
analysis. The expression levels of PMS2 were also similar
(Figure 1B, WB), which is consistent with our previous
observation that the C-terminal domains of MLH1 sufﬁce
for stabilizing PMS2 (31). Accordingly, mutations in the
N-terminus of MLH1 are unlikely to affect formation of a
stable MutLa heterodimer, providing that the mutant
MLH1 is stably expressed.
We tested the mismatch repair activity of all mutant
proteins by assessing mismatch repair-mediated reconstitu-
tion of a plasmid restriction site containing a GT mismatch.
All mutations observed in Lynch syndrome either abolished
(MLH1
T117M and MLH1
A128P) or reduced mismatch repair
efﬁciency (MLH1
N64S and MLH1
R265C) in comparison to
wild-type MLH1, conﬁrming that they compromise the
functionality of MLH1 (Figure 1B, MMR). In contrast, the
repair efﬁcacy of the variant MLH1
D132H, which has been
identiﬁed in low-penetrance hereditary cancer families, was
indistinguishable from wildtype.
In order to determine whether the mutations affect the
complex formation of MutLa with MutSa, we assessed bind-
ing of the mutant proteins (either MLH1 of MutLa)t o
MutSa–DNA in a DNA pull-down assay we have previously
used for investigation of this protein complex (28,31,62). In
this assay, DNA beads are incubated with nuclear protein
extract containing the recombinant MutLa protein. Elution
of DNA-bound protein and subsequent western analysis
allows assessing binding of proteins to the DNA substrate.
Under the conditions applied, MutSa binds to the DNA
substrate, and MLH1/MutLa binds to MutSa–DNA to form
a ternary complex, which depends on MutSa (28). In this
assay, addition of ATP triggers a characteristic, MutSa-
dependent increase in binding of MutLa indicating the
formation of the MutLa–MutSa–DNA complex (28).
We have shown that the experimental conditions applied
do not cause non-speciﬁc DNA end-binding of the proteins
(62), which has been suggested to impair experimental
data on interaction. Since binding of MLH1/MutLa is
6578 Nucleic Acids Research, 2006, Vol. 34, No. 22MutSa-dependent (28) and we did not detect any MutSb
[(28) and unpublished observations], MutSa is the predomi-
nant factor in the MutS–MutLa complex observed under
these experimental conditions.






D132H with MutSa–DNA was indistinguishable from
wildtype (data not shown). In contrast, the MLH1
A128P muta-
tion signiﬁcantly impaired interaction with MutSa–DNA
(Figure 1C): although identical protein levels of wild-type
and mutant MLH1 were incubated (Figure 1C, left panel,
‘Loaded’), binding of the mutant MLH1
A128P to MutSa–
DNA was suppressed below western blot detection limit,
while wild-type MLH1 interacted efﬁciently (Figure 1C,
right panel, ‘Eluted from DNA’). The corresponding experi-
ment with the mutant heterodimer MutLa
MLH1 A128P yielded
very weak signals, whose quantiﬁcation showed that its inter-
action was decreased almost ﬁvefold in comparison to wild-
type MutLa. The ﬁnding that the interaction of the mutant
MLH1 subunit was more suppressed than that of the mutant
MutLa heterodimer is in agreement with our previous obser-
vation that PMS2 can very weakly confer binding to MutSa–
DNA (31). However, PMS2 was unable to compensate the
loss of interaction conferred by the MLH1 mutation.
Various reasons can account for the loss of a protein inter-
action due to the mutation of a single residue, including loss
of optimal van der Waals contacts and electrostatic interac-
tions, but also more complex phenomena like conformational
changes within the interaction interface (63). Since the
introduction of the proline may cause structural distortions,
we analyzed this region of MLH1 more closely to conﬁrm
its involvement in interaction with MutSa.
Identification of additional residues important in
MutLa–MutSa interaction
Ala128 is located within the conserved N-terminal ATPase
domains of MLH1 (Figure 2A). For selecting further residues
for testing, we generated a local sequence alignment of
MLH1 and PMS proteins around MLH1 Ala128 to search
for patterns of conservation (Figure 2B), since protein–
protein interaction interfaces are more conserved than non-
functional protein surfaces (64,65). The sequence alignment
shows two highly conserved motifs of the GHKL–ATPase
(motifs G2 and G3) which frame a less conserved stretch
located between the two loops L34 and L56 (see annotations
below the alignment). Ala128 is located within this less
Figure 1. Analysis of cancer-associated MLH1 mutations. (A) The table lists
the six MLH1 missense mutations identified in hereditary human cancer
syndromes which were selected for analysis. Five of these mutations have
been described in patients with the Lynch cancer syndrome, while one
(D132H) has recently been reported to underlie a low-penetrance colorectal
cancer syndrome (60). *The Reported cases column contains the number
of individual reports listed by the International Society for Gastrointestinal
Hereditary Tumours (www.insight-group.org) except for **D132H whose
allele frequency has been determined in the Israelic population (60).
(B) Wild-type MLH1 and the cancer-associated MLH1 mutants were
co-expressed with PMS2 in HEK293T cells. Protein extracts (50 mg) of
untransfected (lane 1) and transfected (lanes 2–7) cells were separated
by SDS–PAGE and protein expression was verified by immuno-
blotting (MLH1
trans. and PMS2
trans., WB, top panel). Endogenous MSH2
(MSH2
endog.) served as loading control (WB, bottom panel). The extracts
were incubated with a mismatched plasmid as detailed in Materials and
Methods. The plasmid contained a restriction site blocked by a G–T
mismatch. Reconstitution of this restriction site by mismatch repair yielded
two plasmid fragments (D) besides linearized vector (L) after separation of
the digestion products in agarose gels. Repair activity of the MutLa mutants
was assessed in direct comparison to wild-type MutLa which was expressed,
processed and analyzed in parallel. Repair levels were quantified relative to
wildtype; n.d., no detectable repair activity. (C) A DNA pull-down assay was
performed to assess interaction of MLH1wt and MLH1
A128P with MutSa-
DNA. Both MLH1 proteins were expressed either alone (top panels) or co-
expressed with wild-type PMS2 to form the heterodimer MutLa (bottom
panels) in HEK293T cells. Equal amounts of protein extract were incubated
with DNA-coupled magnetic beads as detailed in Materials and Methods.
From these incubations, equal aliquots were removed, separated by SDS–
PAGE and checked by immunoblotting to contain identical concentrations of
transfected MLH1 (and PMS2, if applicable) as shown in the left panel
(‘Loaded’). MSH2 was detected in parallel to serve as loading control. Each
incubation was divided in two samples, one of which (‘+’) was supplemented
with ATP (250 mM final concentration). Supernatant was removed and bound
proteins were eluted, separated by SDS–PAGE and detected by immunoblot-
ting (right panels, ‘Eluted from DNA’). MutSa (only MSH2 is shown) and
MutLa (MLH1–PMS2) were detected. PMS2 is visible just above the signal
of MSH2. The MLH1 protein levels eluted from DNA-beads in the MutLa
experiment were densitometrically quantified (DID: Differential integrated
density).
Nucleic Acids Research, 2006, Vol. 34, No. 22 6579conserved stretch. To add more information on candidate
residues for interaction, we generated an homology model
of the NTD of MLH1 and performed ProMate and ConSurf
predictions. ProMate performs structure-based predictions
of protein–protein interaction sites and was derived from
an extensive analysis of transient heterodimeric protein
complexes (56). ConSurf calculates evolutionary sequence
conservation scores and projects them onto the protein
structure, thereby allowing analyzing surface conservation.
We tested ProMate on the known C-terminal dimerization
domain (CTD) of MutL (24,25). Although none of the proba-
bility values ProMate calculated were high enough to pass the
algorithms’ signiﬁcance limit, ProMate correctly assigned the
highest probability values to the experimentally veriﬁed
C-terminal dimer interface (Supplementary Figure B). We
therefore performed the prediction for the homology model
of the NTD of MLH1 (Figure 2C) and in parallel for
the NTD of its E.coli homologue MutL, of which crystal
structures are available (23,26) (Figure 2D). For both
templates, ProMate identiﬁed two surface patches which
showed increased probability to engage in a protein–protein
contact (Figure 2C and D, left panels; marked by circles).
Again, neither of these patches was above the signiﬁcance
limit and therefore required additional evidence (H. Neuvirth,
personal communication).
The projection of the evolutionary conservation of MLH1
or MutL proteins on the surfaces revealed that the potential
interaction patch close to MLH1
A128 also exhibits increased
conservation scores (Figure 2C and D, right panels; marked
by circles), while no conservation is evident for the other
region predicted by ProMate.
Taken together, the bioinformatic analyses suggested that
MLH1 Ala128 is located closely to a surface patch showing
both increased conservation and increased probability of
engaging in a protein–protein interaction. For further muta-
tional analysis we therefore chose residues from this patch,
but also included several residues from its surroundings con-
stituted by b-strands 3–5 of MLH1. We preferentially chose
residues conserved exclusively in MLH1 proteins, since
PMS2 contributed only weakly to the interaction of MutLa
with MutSa (31). We furthermore preferred surface placed,
charged residues, since most protein interactions include elec-
trostatic interactions (66). We selected 14 residues from the
top edge of the extensive b-sheet that backs the MLH1
ATPase (Table 1; Figure 2B and E). Furthermore, we tested
mutations of two highly conserved residues (MLH1
K164E and
MLH1
R182E) that have been reported to abolish DNA binding
of bacterial MutL (67). DNA binding by MutL proteins is
essential for repair (67,68) and has been suggested to be
important for their interaction with MutS proteins, since
this requires DNA substrates of sufﬁcient length (28,32).
Transfection of wild-type MLH1 and all mutant constructs
into HEK293T cells resulted in similar levels of expression
except for MLH1
Y126A (data not shown), which was excluded
from further analysis. Co-transfection of PMS2 again yielded
similar expression levels with wild-type and mutant MLH1
constructs (data not shown).
Six mutations of four residues conferred a practically com-
plete loss of mismatch repair (H112D/A, K118E, R127E
and Y130H/A; Figure 3A). The repair efﬁciency of seven
other mutants was reduced on average by 50%, while ﬁve
mutations achieved close to 100% repair. Mutations that
reduced mismatch repair levels affected residues with higher
conservation than those that left repair efﬁciency largely
unaffected (E71, D121, K123, K134). When more than one
alteration of a residue was analyzed, the more conservative
alteration affected repair less (Y130F, Y157A).
We identiﬁed three residues whose alteration interfered





R127E, Figure 3C), as well as the non-
conservative alterations of Tyr130 (MLH1
Y130H and
MLH1
Y130A, Figure 3D–E) displayed defects in binding to
MutSa–DNA. Identically to MLH1 A128P, these mutations
decreased the level of bound MLH1 below western blot
detection limit. The corresponding mutant MutLa proteins
again retained some weak binding (also as observed with
A128P), which was presumably conferred by PMS2. All
other mutants, including the conservative alteration
MLH1
Y130F (Figure 3F) interacted with MutSa–DNA
identically as wildtype (data not shown).
It has previously been shown that mutations in the ATPase
domain can abolish hydrolytic activity of MutLa without
affecting its ability to interact with MutSa (29). However,
to rule out that an alteration of the ATPase activity may
have indirectly abolished interaction, we tested the ATPase
activity of the interaction-deﬁcient H112 mutants.
GST–MutLa
wt, GST–MutLa
MLH1 H112D/A and the previously
characterized catalytic residue mutant GST–MutLa
MLH1 E34A
were expressed and puriﬁed. Our experiments conﬁrmed




Asn 64 Ser L Exp. c
Glu 71 Lys L Exp. mc
Asp 72 Lys L Exp. c
His 112 Asp, Ala b Exp. c (in MLH1)
Thr 117 Met b Bur. c
Lys 118 Glu b Exp. mc (in MLH1)
Asp 121 His L Exp.
Lys 123 Glu L Exp.
Tyr 126 Ala b Bur. c (in MLH1;
either Y or W )
Arg 127 Glu b Exp. mc
Ala 128 Pro b Bur. c
Tyr 130 His, Ala, Phe b Bur. c (in MLH1;
either Y or F)
Asp 132 His L Exp. c
Gly 133 Asn L Exp. c
Lys 134 Gly, Glu L Exp. mc
Lys 140 Glu b Exp. mc (in MLH1)
Asp 154 Lys L Exp. mc (in MLH1)
Tyr 157 Lys, Ala L Exp. c (in MLH1)
Lys 164 Glu Exp. c
Arg 182 Glu Exp. c
Arg 265 Cys L Bur. c
The table lists MLH1 mutations which have been used in this study for screen-
ingforresiduesinvolvedintheinteractionofMutLawithMutSa-DNA.Muta-
tions involved in human cancer diseases are printed in italics.
aLocalization of the residue within MLH1 according to the homology model:
the first column informs in what secondary structure the residue is located (b:
b-sheet; L: loop), while the second column gives the exposition status (Exp.:
exposed; Bur.: buried).
bThe conservation column summarizes the evaluation of conservation of the
residues according to Figure 2B (c, conserved; mc, mostly conserved).
6580 Nucleic Acids Research, 2006, Vol. 34, No. 22Figure 2. Analysis of the sequence and structure of hMLH1. (A) Schematic diagram of MLH1. MLH1 contain conserved N-terminal GHKL-ATPase (‘ATPase’)
and C-terminal dimerization domains (‘dimerization’). The locations of the cancer-associated mutations investigated in this work are marked by asterisks.
(B) Local multiple sequence alignment surrounding A128 from the hMLH1 ATPase (hMLH1 aa 98–164). The sequences were retrieved by a Protein-BLAST
search for sequences homologous to human MLH1 (top) or PMS2 (bottom) and aligned together with the E.coli MutL sequence (middle) using ClustalW (50)
with subsequent small manual modifications. The residue numbering above the alignment refers to hMLH1, and the secondary structure information shown
below the alignment refers to the crystal structure of E.coli MutL (23,26). The alignment comprises b-strands 3–6 and, in part, the neighbouring a-helices D and
E, including conserved motifs of the GHKL–ATPases (motif III, G2-box and motif IV, G3 box (22)). Coloured shading indicates similarity or identity of amino
acids (matrix: Blosum62, shading threshold 40%, calculated for all sequences. Colour coding: yellow for hydrophobic residues, blue for positively charged
residues, red for negatively charged residues, pink for other residues). Mutations associated with hereditary human cancer are marked by asterisks, and mutations
investigated in this study are annotated above the alignment. (C) A homology model of the N-terminal domains of MLH1 (residues 1–335) was generated (for
details see Materials and Methods) and used for interaction-site prediction with ProMate (left) and projection of phylogenetic conservation with ConSurf (right)
as detailed in Materials and Methods. ProMate enabled shading of the surface of the model according to the predicted probability of the residues to contribute to a
transient protein–protein interaction, with red shading representing high probability and blue shading showing low probability. The ConSurf prediction is
presented with red shading for conserved residues and blue shading for variable residues. Circles mark the candidate interaction sites which are discussed in the
results section. (D) The same analysis as described in C was performed for the crystal structure of the NTD of E.coli MutL (PDB 1B63). (E) Cartoon
representation of the homology model of the MLH1 NTD in the same orientation as the surface representation of C. The bound nucleotide is presented in spheres
colour-coded according to the elements. Cancer-associated residues investigated in this study are presented as blue spheres with framed annotations. Residues
that were selected for further mutational investigation are annotated.
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MLH1 E34A has no
detectable ATPase activity (Figure 3G) while retaining inter-
action with MutSa (data not shown). In contrast, GST–
MutLa
wt and the interaction-deﬁcient GST–MutLa
MLH1
H112D displayed identical ATPase activity (Figure 3G),
which was very similar to the previously determined activity
of MutLa (29). This conﬁrms that the H112D mutation did
not abolish interaction indirectly by affecting the ATPase.
E.coli MutL interacts with MutS with the same protein
surface
Since the bioinformatic analysis suggested that a potential
protein–protein interaction site with elevated surface conser-
vation in E.coli MutL is located similarly as in MLH1, we
tried to site-speciﬁcally crosslink MutS to a residue in this
putative interface of MutL. We have previously applied
crosslinking for the mapping of the interaction sites of
MutL and MutH (45,46). Here we used the E.coli single-
cysteine variant MutL
N131C containing a cysteine residue
located in loop L45 (N131 is marked in Figure 2B) at the
edge of the potential MutS interface (46). After incubation
of MutL
N131C with MutS under conditions suitable for
mismatch-provoked activation of the strand discrimination
endonuclease MutH (46), we applied the homobifunctional
reagent BM[PEO]4. This reagent crosslinks cysteine residues
which are located in proximity [3–17 s, (69)]. After separa-
tion of the crosslinking products by SDS–PAGE, Coomassie
staining revealed the formation of two high molecular weight
products: one which occurred in all experiments including
MutL
N131C and has previously been assigned as the MutL–
MutL (L–L) crosslink (46) (Figure 4A). The other product
formed exclusively in the presence of MutL
N131C, MutS,
ATP and DNA with an apparent molecular weight corre-
sponding to a crosslinked MutL
N131C–MutS (S–L) complex.
The presence of both MutL and MutS proteins in this band
was conﬁrmed by tryptic digest and massspectrometry (data
not shown). This suggests that Asn131 of MutL is close to
one of the six cysteine residues in MutS.
In addition, we tested the heterobifunctional crosslinking
reagent maleimido-benzophenone (MBP) that after coupling
to a cysteine residue allows photocrosslinking to suitable
acceptor residues in proximity to the benzophenone moiety
(70). Again, a new band with low electrophoretic mobility
was only observed in reactions containing MutS, MutL
N131C,
ATP and DNA (Figure 4B). The lower mobility of the
Figure 3. Analysis of MLH1 mutants for MMR activity and interaction with MutSa–DNA. (A) Nineteen MLH1 missense mutants were co-expressed with PMS2
in parallel to wild-type MutLa in HEK293T cells and in vitro mismatch repair activity was assessed as described in Figure 1 and Materials and Methods. AseI
digestion of the mismatched test plasmid yielded linearized vector (L), and successful repair additionally produced two fragments of lower molecular weight (D,
digestion fragments). Repair activity of each MutLa mutant was assessed in direct comparison to wild-type MutLa which was expressed, processed and analyzed
in parallel, and repair levels were quantified in relation to these wild-type preparations. These levels (wildtype ¼ 1.0) are shown; n.d., no detectable repair




Y130H/A/F with MutSa–DNA was assessed in comparison to MLH1wt
identically as described in Figure 1. (G) The ATPase activity of purified GST–MutLa mutants was assessed in comparison to wildtype as detailed in Materials
and Methods. Three individual experiments were performed for each protein preparation and for a mock sample without protein. Values of the mock samples
were subtracted from the protein samples. The block diagrams show the average ATPase activity, with error bars giving the standard deviations.
6582 Nucleic Acids Research, 2006, Vol. 34, No. 22photocrosslink product compared to the cysteine–cysteine-
crosslinked product may be a result of crosslinking to a
residue in MutS located in the middle of the protein rather
than the end, a phenomenon which we observed for a variety
of single-cysteine MutL variants (unpublished observations).
The presence of the E.coli MutL interaction partner MutH,
which physically interacts with the NTD of MutL (46)
did not affect formation of the MutS–MutL
N131C crosslink
products, suggesting that MutH does not interfere with
complex formation of MutL with MutS.
DISCUSSION
In the present study, information on MLH1 mutations in
human cancer diseases, bioinformatic analyses and in vitro
assays served to identify four residues in human MLH1
whose mutation interfered with the interaction of MutLa
(MLH1–PMS2) with MutSa. All mutations that abolished
interaction also disabled the mismatch repair activity of
MutLa. Therefore, we provided experimental evidence that
the MutLa–MutSa interaction is required for mismatch
repair.
In the present experiments, the investigated mutations
could in principle have affected the MutLa–MutSa interac-
tion in three ways: (i) the mutation could directly abolish
the interaction interface; (ii) the mutation could confer an
indirect effect on interaction by affecting the ATPase activity
of MLH1; (iii) the mutation could abolish interaction with
another protein that mediates the MutLa–MutSa complex,
since nuclear extracts were used. However, it is most likely
that the analyzed mutants affected the interaction interface
directly for the following reasons: (i) the data from the muta-
tional analysis is consistent with bioinformatic evidence indi-
cating a conserved protein–protein interaction site in the
investigated position; (ii) the crosslinking experiments with
the homologue MutL reﬂected a direct physical contact;
(iii) the interaction-deﬁcient mutant MutLa
MLH1 H112D had
wild-type ATPase activity; (iv) the applied method efﬁciently
captures complexes of puriﬁed MutLa and MutSa (28),
excluding a prominent involvement of a mediator protein.
Two of the identiﬁed mutations affected charged surface
residues (His112 and Arg127). The positive charge of
His112 is very conserved in eukaryotic MLH1 (either His,
Arg or Lys) and bacterial MutL (exclusively Arg), while
this position is variable in PMS proteins (Figure 2B). This
suggests that the positive charge in this position is vital for
a functional interaction of MLH1 with MutSa. The other
charged surface residue, Arg127, also shows very high con-
servation of the positive charge, but this is also true for
PMS proteins, while MutL proteins have glutamine in this
position. Two further mutations affected buried residues
(Ala128 and Tyr130). The Ala128Pro mutation most likely
disrupts the b-strand b4 and thereby distorts the b-sheet. In
the position of Tyr130, bulky hydrophobic residues are
conserved, suggesting that hydrophobic interactions of this
residue contribute to the structural integrity of this protein
region. Accordingly, the conservative alteration of Tyr130
to phenylalanine (MLH1
Y130F) impaired neither interaction
nor mismatch repair. All three mutations (Ala128Pro,
Tyr130His/Ala) therefore seem incompatible with maintain-
ing the structural integrity of the interaction interface.
All identiﬁed residues cluster in a small region of MLH1,
suggesting that the major MutLa interaction interface for
MutSa is (at least partly) constituted by residues from
two adjacent b-strands (b3–b4) on the edge of an extensive
b-sheet that backs the ATP binding pocket of MLH1
(Figure 5A). E.coli MutL could be site-speciﬁcally
crosslinked to MutS from a residue in the corresponding
Figure 4. Crosslinking of E.coli MutL
N131C to MutS. (A) Crosslinking was
performed using E.coli MutS (400 nM), MutL
N131C (1000 nM) and a 484 bp
DNA substrate (100 nM) in the presence of the indicated nucleotide (1 mM)
as detailed in Materials and Methods. BM[PEO]4 was added to a final
concentration of 50 mM and the reaction was incubated for 1 min at 37 C.
Crosslinking was quenched by addition of 50 mM DTT, and the products
were separated by SDS–PAGE and protein bands were visualized by colloidal
Coomassie staining that also stains DNA. Note that the additional band
attributed to a MutS–MutL
N131C crosslink (S–L
N131C) is only observed in the
presence of both ATP and DNA. (B) Photocrosslinking of MutL
N131C was
carried out in the presence or absence of MutH
C96S. Both proteins were pre-
incubated at 10 and 2.5 mM, respectively, with 500 mM MBP in the presence
of 4 mM nucleotide, ATP or AMP–PNP, for 30 min at room temperature.
Reactions were stopped by adding DTT. For photocrosslinking, 2 mM
modified MutL, 500 nM MutH, 1 mM MutSwt, 0.8 mM nucleotide and 25 nM
484 bp mismatch DNA were irradiated for 25 min at 354 nm. The products
were separated by SDS–PAGE and visualized by Coomassie staining without
staining the DNA.
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site. This is corroborated by the bioinformatic evidence,
which suggested a similarly placed putative protein interac-
tion site for MutL as for MLH1.
The interaction interface is easily accessible even when the
N-terminal ATPase domains of MutLa dimerize similarly as
has been described for E.coli MutL (Figure 5B). The contact
of MLH1 to MutSa–DNA could therefore in principle be
maintained by any intermediate of the ATPase cycle of
MutL proteins, which involves this transient N-terminal
dimerization. Since the interaction interface is located in
immediate proximity to the MLH1 ATPase, interaction is
very likely to modulate its activity. It will be interesting to
investigate the nature of this modulation, since this may
help disclose how mismatch recognition and repair are
communicated from MutS to MutL and then to the down-
stream enzymes of mismatch repair. The presently identiﬁed
mutations may facilitate such investigations, since they allow
selectively disabling MutL–MutS complex formation.
During evolution, the homodimeric bacterial MutS and
MutL proteins have changed to the heterodimeric complexes
that are present in eukaryotic organisms. This process
involved a specialization of the dimeric subunits as is exem-
pliﬁed by the ﬁnding that only one subunit of the eukaryotic
MutSa/b heterodimers (MSH3/6) has retained the residues
required for mismatch recognition, while these residues
have been lost in their MSH2 partner. Our previous work
already suggested that the interaction of two different
human MutL heterodimers (MutLa, MLH1–PMS2, and
MutLb, MLH1–PMS1) with MutSa depends predominantly
on their MLH1 subunit (31). The present ﬁndings conﬁrm
that mutations in the NTD of MLH1 sufﬁce to abolish inter-
action of MutLa with MutSa. This conﬁrms the signiﬁcance
of MLH1 over its PMS partners in MutL–MutS interactions
and suggests that MLH1 may have specialized to a general
interaction adaptor responsible for docking human MutL
heterodimers to their MutS partners, while the PMS family
of proteins has (mostly) lost this ability.
The present study revealed that the cancer-associated
mutation MLH1
A128P affects a residue located within the
MutLa–MutSa interaction interface. This mutation disabled
in vitro mismatch repair by destroying the ability of MutLa
to interact with MutSa (although other functions of MLH1
may also be affected by the mutation). The MLH1
A128P muta-
tion has been identiﬁed in an Italian kindred with a classical
Lynch syndrome meeting the clinical Amsterdam criteria
(71). In the affected family, several members suffered from
cancer occurring at young age. The present ﬁndings are in
good agreement with the severe clinical phenotype.
Asecondcancer-associatedmutation,MLH1
D132H,affectsa
residue located very closely to the interaction interface,but the
mutation did not detectably affect DNA mismatch repair or
MutSa interaction in our experiments. The MLH1
D132H muta-
tionisextraordinarysincethecancerpredispositionitconfersis
untypical for Lynch syndrome (60). Tumours of affected indi-
vidualsrarelyshowedmicrosatelliteinstability(MSI),whichis
a genetic hallmark of deﬁcient mismatch repair and typically
observed in Lynch syndrome tumours. The meanage of cancer
onset was signiﬁcantly higher and the penetrance within the
family appeared lower than in Lynch syndrome. Our ﬁnding
that DNA mismatch repair was not detectably impaired by
this mutation explains the rare occurrence of tumour MSI and
the attenuated phenotype. Further studies will have to clarify
if the low-penetrance cancer predisposition of this mutation is
the result of a DNA mismatch repair defect that is too weak to
be detectable by the applied in vitro mismatch repair assay or
the mutation affects another function of MLH1.
In conclusion, our work identiﬁes the interaction interface
of MutLa for MutSa within MLH1. This interaction interface
is also conserved in bacterial MutL proteins. Mutations in this
interface in MLH1 sufﬁce to abolish interaction of the MutLa
heterodimer with MutSa and result in a MutLa heterodimer
deﬁcient for mismatch repair. One cancer-associated muta-
tion which is located within this interaction interface abol-
ishes interaction and repair, underlining the importance of
this complex for mutation avoidance.
Figure 5. Localization of the MutLa–MutSa interaction interface on MLH1. (A) Cartoon presentation of the N-terminal MutLa dimer generated by
superimposing the homology model of MLH11–335-ATP (shown in green) and the crystal structure of PMS231-364-ATPgS (72) (PDB 1H7U; shown in grey) on the
crystal structure of the N-terminal homodimer of E.coli MutL1-329-AMP-PNP (26) (PDB 1B63). The C-terminal constitutive dimerization domains are
schematically added below the model (not to scale). The nucleotide phosphates are presented in sticks in the ATP binding pockets, which are backed by extensive
b-sheets. Residues whose mutation interfered with MutLa–MutSa interaction (presented in spheres) are clustered on the top edge of this b-sheet of the MLH1
subunit. (B) Surface presentation of A. Buried or surface residues whose mutation abolished interaction are coloured red and orange, respectively. The MLH1
residue homologous to MutL
N131 which has been crosslinked to MutS is coloured dark blue, while other investigated residues without detectable effect on
interaction are coloured cyan. The region that the ProMate and ConSurf analyses suggested as interaction interface (Figure 2C) is marked by a white line.
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